Randomised double blind trial of prednisone and naproxen in treatment of crystal proven acute gout

ISRCTN ISRCTN14648181
DOI https://doi.org/10.1186/ISRCTN14648181
Secondary identifying numbers N/A
Submission date
20/12/2005
Registration date
20/12/2005
Last edited
03/06/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Not provided at time of registration

Contact information

Dr Eloy van de Lisdonk
Scientific

Department of General Practice and Family Medicine
Radboud University
P.O. Box 9191
Nijmegen
6500 HB
Netherlands

Phone +31 (0)24 3615311
Email e.vandelisdonk@hag.umcn.nl

Study information

Study designRandomised, double blind, active controlled, parallel group trial.
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study acronymPREDJ-study (PREDnison Jicht = gout)
Study hypothesisActive treatment of acute gouty arthritis by a short course of oral prednisone or naproxen are equal.
Ethics approval(s)Ethics approval received from the local medical ethics committee
ConditionAcute gout
InterventionFive days, by oral administration, either prednisolone 35 mg (= 30 mg prednisone) once a day or naproxen at a dose of 500 mg twice a day. Patients received blind capsules containing active prednisolone and placebo naproxen, or active naproxen and placebo prednisolone.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Prednisone, naproxen
Primary outcome measurePatient assessment of pain in the study joint, indicated on visual analogical scales two times a day, during 4 days.
Secondary outcome measures1. PatientsÂ’ global disability
2. The walking disability, if the study joint was in the leg or foot
3. Safety and tolerability of prednisone versus naproxen
Overall study start date01/04/2004
Overall study end date01/06/2006

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexNot Specified
Target number of participants120
Participant inclusion criteriaAll patients referred to the rheumatology department of one hospital, by their general practitioner because of mono-arthritis, who proved to have urate crystals after diagnostic joint aspiration.
Participant exclusion criteria1. Use of anti-trombolytica
2. A history of peptic ulcer
3. A history of reduced renal function
4. A history of heart failure
5. A known hypersensitivity to naproxen and/or prednisone
6. Use of any Non-Steroidal Anti-Inflammatory Drug (NSAID) or prednisone within the past 12 hours
7. Unwillingness to participate
Recruitment start date01/04/2004
Recruitment end date01/06/2006

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Department of General Practice and Family Medicine
Nijmegen
6500 HB
Netherlands

Sponsor information

University Medical Center St. Radboud (The Netherlands)
Hospital/treatment centre

Department of General Practice and Family Medicine
P.O. Box 9101
Nijmegen
6500 HB
Netherlands

Website http://www.umcn.nl/homepage
ROR logo "ROR" https://ror.org/05wg1m734

Funders

Funder type

Hospital/treatment centre

University Medical Center St. Radboud (The Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article Results 31/05/2008 Yes No